JP5406530B2 - 親水性ベヒクルに基づく二重制御された放出マトリクスシステム - Google Patents

親水性ベヒクルに基づく二重制御された放出マトリクスシステム Download PDF

Info

Publication number
JP5406530B2
JP5406530B2 JP2008538048A JP2008538048A JP5406530B2 JP 5406530 B2 JP5406530 B2 JP 5406530B2 JP 2008538048 A JP2008538048 A JP 2008538048A JP 2008538048 A JP2008538048 A JP 2008538048A JP 5406530 B2 JP5406530 B2 JP 5406530B2
Authority
JP
Japan
Prior art keywords
agent
matrix
hydrogel
hydrophilic vehicle
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008538048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009513669A5 (enExample
JP2009513669A (ja
Inventor
カルナカル スクル，
Original Assignee
バナー ファーマキャプス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バナー ファーマキャプス， インコーポレイテッド filed Critical バナー ファーマキャプス， インコーポレイテッド
Publication of JP2009513669A publication Critical patent/JP2009513669A/ja
Publication of JP2009513669A5 publication Critical patent/JP2009513669A5/ja
Application granted granted Critical
Publication of JP5406530B2 publication Critical patent/JP5406530B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008538048A 2005-10-26 2006-10-26 親水性ベヒクルに基づく二重制御された放出マトリクスシステム Expired - Fee Related JP5406530B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73040605P 2005-10-26 2005-10-26
US60/730,406 2005-10-26
PCT/US2006/042177 WO2007050975A2 (en) 2005-10-26 2006-10-26 Hydrophilic vehicle-based dual controlled release matrix system as capsule fill

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013133677A Division JP2013216680A (ja) 2005-10-26 2013-06-26 親水性ベヒクルに基づく二重制御された放出マトリクスシステム

Publications (3)

Publication Number Publication Date
JP2009513669A JP2009513669A (ja) 2009-04-02
JP2009513669A5 JP2009513669A5 (enExample) 2009-12-17
JP5406530B2 true JP5406530B2 (ja) 2014-02-05

Family

ID=37801480

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008538048A Expired - Fee Related JP5406530B2 (ja) 2005-10-26 2006-10-26 親水性ベヒクルに基づく二重制御された放出マトリクスシステム
JP2013133677A Pending JP2013216680A (ja) 2005-10-26 2013-06-26 親水性ベヒクルに基づく二重制御された放出マトリクスシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013133677A Pending JP2013216680A (ja) 2005-10-26 2013-06-26 親水性ベヒクルに基づく二重制御された放出マトリクスシステム

Country Status (6)

Country Link
US (1) US8333989B2 (enExample)
EP (1) EP1959935A2 (enExample)
JP (2) JP5406530B2 (enExample)
CN (1) CN101360485B (enExample)
CA (1) CA2627292C (enExample)
WO (1) WO2007050975A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE487470T1 (de) * 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP1993559B1 (en) 2006-02-03 2016-06-22 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
JP2010525080A (ja) 2007-04-25 2010-07-22 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
HRP20231142T3 (hr) 2007-04-25 2024-01-05 Eirgen Pharma Ltd. Kontrolirano oslobađanje 25-hidroksivitamina d
EP2907524A1 (en) 2007-05-25 2015-08-19 RB Pharmaceuticals Limited Sustained delivery formulations of risperidone compounds
ES2954932T3 (es) 2008-04-02 2023-11-27 Eirgen Pharma Ltd Métodos, composiciones, usos y kits útiles para la deficiencia de vitamina D y trastornos relacionados
CN101485707B (zh) * 2009-02-23 2011-05-18 四川珍珠制药有限公司 一种灵丹草软胶囊及其制备方法
CN101491549B (zh) * 2009-02-23 2011-08-03 四川珍珠制药有限公司 一种中药软胶囊及其制备方法
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US20150250750A1 (en) * 2012-10-16 2015-09-10 Wockhardt Limited Pharmaceutical compostions of diclofenac or salts thereof
WO2014060857A1 (en) * 2012-10-19 2014-04-24 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
HK1220113A1 (zh) * 2013-03-15 2017-04-28 Warner Chilcott Company, Llc 药物软明胶胶囊剂型
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
RU2676480C2 (ru) * 2013-03-15 2018-12-29 УОРНЕР ЧИЛКОТТ КОМПАНИ, ЭлЭлСи Фармацевтическая дозированная лекарственная форма в виде мягкой желатиновой капсулы, содержащая модифицированную гуаровую камедь
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
CA2939990C (en) 2014-02-28 2018-07-10 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10772842B2 (en) 2015-01-09 2020-09-15 Patheon Softgels Inc. Abuse-deterrent opioids
WO2015157138A1 (en) 2014-04-07 2015-10-15 Banner Life Sciences Llc Abuse-deterrent controlled release formulations
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20180071221A1 (en) * 2015-03-02 2018-03-15 Bionpharma Healthcare Llc Immediate release soluble ibuprofen compositions
CN108883120A (zh) 2016-03-28 2018-11-23 欧普科爱尔兰环球控股有限公司 维生素d治疗方法
JP7112409B2 (ja) * 2017-01-24 2022-08-03 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 抗Ｆｅｌ Ｄ１抗体を含む組成物及びヒトのネコアレルギーの少なくとも１つの症状を減少させる方法
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
IL301692A (en) * 2020-10-16 2023-05-01 Scherer Technologies Llc R P Controlled release fill compositions and capsules containing same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947600A (en) * 1973-10-12 1976-03-30 General Foods Corporation Dipeptide sweetening of comestibles
US4708834A (en) * 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
FR2642650B1 (fr) * 1989-02-09 1994-12-09 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines
JPH0717498B2 (ja) * 1989-05-31 1995-03-01 興和株式会社 鎮咳去痰ソフトカプセル剤
CA2017916C (en) * 1989-06-07 1999-02-02 Minoru Aoki Etoposide preparations
CA2107678A1 (en) * 1991-04-08 1992-10-09 Kouichi Nakamichi Capsule
US5505961A (en) * 1993-08-05 1996-04-09 R. P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution
GB9322314D0 (en) 1993-10-29 1993-12-15 Scherer Ltd R P Foam generating capsules
SK96196A3 (en) * 1994-01-24 1997-03-05 Procter & Gamble Process for solubilizing difficultly soluble pharmaceutical actives
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
FR2748209B1 (fr) 1996-05-06 1998-06-05 Adir Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
BE1011363A3 (fr) * 1997-09-11 1999-08-03 Smb Technology Capsules semi-solides autoemulsionnables matricielles a action prolongee.
GB2331458B (en) * 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
CA2318128C (en) * 1998-01-20 2008-10-14 Applied Analytical Industries, Inc. Oral liquid compositions
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
US6251426B1 (en) * 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
HK1044485A1 (zh) 1999-09-27 2002-10-25 American Cyanamid Company 药物载体配方
DE60028754T2 (de) 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US6607736B2 (en) * 1999-12-20 2003-08-19 Shiseido Company, Ltd. Skin preparations for external use
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
JP2003055254A (ja) * 2001-08-17 2003-02-26 Toyo Capsule Kk 経口投与用シクロスポリン製剤
US7029698B2 (en) * 2001-11-21 2006-04-18 R.P. Scherer Technologies, Inc. Acetaminophen compositions
MXPA04006875A (es) * 2002-01-18 2004-12-06 Control Delivery Sys Inc Sistema de gel polimerico para suministro controlado de cofarmacos.
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
US20040033257A1 (en) * 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
WO2004004693A1 (en) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
EP1545475B1 (en) 2002-10-01 2014-07-16 Banner Pharmacaps, Inc. Enteric composition for the manufacture of soft capsule wall
DK2279729T3 (da) 2003-07-17 2016-11-28 Banner Life Sciences Llc Præparater med kontrolleret frigivelse
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
CN1909891A (zh) * 2004-01-09 2007-02-07 惠氏公司 药用组合物的微乳液
WO2006133048A2 (en) * 2005-06-03 2006-12-14 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same

Also Published As

Publication number Publication date
EP1959935A2 (en) 2008-08-27
US8333989B2 (en) 2012-12-18
WO2007050975A3 (en) 2007-09-20
CN101360485A (zh) 2009-02-04
JP2013216680A (ja) 2013-10-24
WO2007050975A2 (en) 2007-05-03
CN101360485B (zh) 2013-04-17
JP2009513669A (ja) 2009-04-02
CA2627292A1 (en) 2007-05-03
CA2627292C (en) 2012-04-17
US20070098783A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
JP5406530B2 (ja) 親水性ベヒクルに基づく二重制御された放出マトリクスシステム
JP5406529B2 (ja) カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム
RU2163803C2 (ru) Фармацевтические композиции, содержащие дарифенацин
TWI257302B (en) Controlled-release of an active substance into a high fat environment
KR100882707B1 (ko) 라모트리진을 포함하는 서방형 제제
JP5580815B2 (ja) 経粘膜デリバリーシステム
US20150250733A1 (en) Oral drug delivery formulations
JP2007509155A (ja) クエチアピンを含有する薬剤
JPH10502376A (ja) 新規ドラッグデリバリーシステム
BR112015020453B1 (pt) Formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe
JP2006188539A (ja) エチルセルローズ水性分散液で被覆した放出制御製剤
HRP20030082A2 (en) Hydrogel-driven drug dosage form
EP2563345A2 (en) Layered drug delivery device
WO2009066146A2 (en) Stable solutions of sparingly soluble actives
AU2013290875A1 (en) Gastro-retentive drug delivery system
WO2014154029A1 (zh) 复合骨架材料及其药物组合物
TW201534357A (zh) 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
Tayel et al. Formulation of ketotifen fumarate fast-melt granulation sublingual tablet
US20050048118A1 (en) Modified release venlafaxine hydrochloride tablets
CN106572980A (zh) 包含他喷他多的防篡改即释胶囊制剂
KR20230088388A (ko) 변형 방출 소프트겔 캡슐
MX2008005474A (en) Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
MX2008005470A (en) Lipophilic vehicle-based dual controlled release matrix system as capsule fill
HK1259508B (zh) 氘代多潘立酮组合物和用於治疗病症的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091026

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121018

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130815

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131101

R150 Certificate of patent or registration of utility model

Ref document number: 5406530

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees